Bionomics Announces Positive Results from Phase 2 Trial of BNC210 in Generalized Anxiety Disorder
Both primary endpoints met with a high level of significance; suggests potential for paradigm change for treatment of anxiety disorders
BNC210 suppressed activation of the amygdala out-performing standard of care, lorazepam (Ativan)
BNC210 caused significant changes in cerebral perfusion, measured by brain imaging, consistent with anti-anxiety activity
Secondary endpoint met with a high level of significance; BNC210 suppressed anxietyrelated defensive behaviour in the Joystick Operated Runway Task, out-performing lorazepam
Phase 2 results strengthen BNC210 licensing package and provide a significant boost to partnering prospects
